Health Condition 1: N70-N77- Inflammatory diseases of female pelvic organs
Conditions
Interventions
Intervention1: Tab Mirabegron50 mg: At 24 and 1 hr before surgery
Control Intervention1: look alike placebo Placebo: similar time as intervention
Sponsors
AIIMS Bhubaneswar
Eligibility
Inclusion criteria
Inclusion criteria: 1-Undergoing elective gynecological surgery under general anesthesia requiring postoperative urinary catheterization 2-Surgical duration is less than 4 hr.
Exclusion criteria
Exclusion criteria: 1-History of Coronary artery disease. Hypertension > 150mmHg in initial 48hrs before surgery, Patient on Digoxin, or Drugs are known to prolong the QT/QTc interval. 2-Known bladder dysfunction, such as overactive bladder, neurogenic bladder 3-Pregnant or breastfeeding 4-Intellectual disability 5-Chronic renal insufficiency (creatinine >1.5mg/dL) or liver insufficiency (bilirubin >34.2mmol/L),
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the effect of oral mirabegron 50 mg and placebo (as control) on the incidence of CRBD after elective gynecologic surgery under general anesthesia at 1st hr. after surgeryTimepoint: 1 hr | — |
Secondary
| Measure | Time frame |
|---|---|
| 1To compare the effect of oral mirabegron 50 mg and placebo on the incidence of CRBD at 0, 2nd and 6th hr and severity of CRBD at 0, 1st, 2nd and 6th hr after surgery. Timepoint: 0, 1st, 2nd and 6th hr;any side effect of mirabegronTimepoint: 6hr;Opioid requirement during the postoperative period following 12 hours of surgery.Timepoint: 12hr;Patient satisfaction between two groups at 6hr using GPE scaleTimepoint: 6hr;PONV between groupsTimepoint: 12hr;to compare VAS score between groupsTimepoint: 12hr | — |
Countries
India
Contacts
Public ContactDr Alok Kumar Sahoo
AIIMS, Bhubaneswar
Outcome results
None listed